 |
|
Isogeneic Marrow Grafts for Hematologic Malignancy in Man
Robert H. Rudolph, MD;
Alexander Fefer, MD;
E. Donnall Thomas, MD;
C. Dean Buckner, MD;
Reginald A. Clift, FIMLT;
Rainer Storb, MD
Arch Intern Med. 1973;132(2):279-285.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Since total body irradiation can exert an antileukemic effect, and since death from aplasia induced by otherwise lethal doses of whole body irradiation can be prevented by infusion of isogeneic marrow, attempts have been made to treat patients having acute leukemia with total body irradiation and infusion of marrow from an identical twin.1-3 Although this approach occasionally has been effective in some animal models,4-6 its effect in man has been discouraging because leukemia has recurred within 7 to 12 weeks.7
This report describes results of treatment of five patients having hematologic malignant neoplasms refractory to conventional therapy. These patients were treated with supralethal total body irradiation and isogeneic marrow infusion. One was given maintenance chemotherapy immediately after grafting and four of the patients received "immuno-therapy." The latter was based largely on the assumed existence of tumor-specific antigens on human leukemic cells,8-11 on studies of eradication of
. . . [Full Text PDF of this Article]
Author Affiliations
Seattle
From the Department of Medicine, University of Washington School of Medicine, and the Public Health Service Hospital, Seattle. Dr. Rudolph is now at the Mason Clinic, Seattle.
Footnotes
Received for publication March 27, 1972; accepted June 16.
Reprint requests to Division of Oncology, University of Washington, Seattle 98195 (Dr. Thomas).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
